Page 4 - Pharma Industry

Indian pharma faces US revenue slowdown amid scrutiny, tariffs: ICRA

ICRA projects Indian pharma firms' US revenue growth to slow due to price erosion, USFDA scrutiny and tariff risks, while high dependence on Chinese APIs persists despite PLI

Lupin gets USFDA nod for generic cancer drug Lenalidomide capsules

Lupin has received USFDA approval for generic Lenalidomide capsules in six strengths, adding to competition in the US oncology market for Bristol-Myers Squibb's Revlimid

Mankind joins hands with OpenAI to institutionalise AI in operations

"GPT-powered dashboards will be used to provide real-time, data-driven insights across R&D, supply chain and commercial operations," a company executive told Business Standard

NPPA asks pharma firms to pass on GST rate cut benefits from Sept 22

The National Pharmaceutical Pricing Authority has asked pharmaceutical companies and medical device makers to pass on the benefit of reduced GST rates to consumers with effect from September 22. "The benefit of reduction in GST rates shall be passed on to consumers/patients effective from September 22, 2025. All the manufacturers /marketing companies selling drugs/formulations shall revise theP of drugs/formulations (including medical devices) accordingly, with effect from September 22," the authority said in an order. The manufacturer and marketing companies shall issue a revised price list or supplementary price list to the dealers, retailers, state drug controllers and the government, reflecting the revised GST rates and revisedP, the National Pharmaceutical Pricing Authority (NPPA) stated. Manufacturer and marketing companies shall take immediate measures to sensitise dealers, retailers, and consumers about the reduction in GST rates through all possible channels of communicatio

NPPA asks pharma, medtech firms to cut prices after GST rate reduction

NPPA directs pharma and medical device makers to revise MRPs after GST cut to 5 per cent, while making relabelling of old stock voluntary subject to compliance

Biocon expands US footprint with new Cranbury manufacturing facility

Biocon inaugurated its first US manufacturing facility in Cranbury through Biocon Generics, expanding its global footprint and strengthening supply chains for essential therapies

Shukra Pharma enters into pan-India distribution pact with Wockhardt

Shukra Pharmaceuticals on Wednesday said it has entered into a strategic non-exclusive Pan-India distribution arrangement with Wockhardt Ltd. The authorization is effective from September 9, 2025 and is valid until March 2026, an exchange filing said. The products include advanced anti-infective formulations and antibiotics developed to combat critical infections. The mandate includes distribution and management of products across all ESIC/ESIS hospitals and Defence/AFMSD/DGAFMS units throughout India, the filing said. "This collaboration further strengthens Shukra Pharmaceuticals presence in institutional and government healthcare networks across India, enhancing revenue visibility and operational footprint," the company said. Shukra Pharmaceuticals Limited is engaged in manufacturing and marketing pharmaceutical products as well as laboratory testing.

Sun Pharma stock concerns may be overstated as domestic growth holds

Analysts say Sun Pharma's stock concerns are overdone, with strong domestic growth, broad-based chronic portfolio gains and resilient Q1FY26 earnings offsetting US market worries

Glenmark gains 3% on $700 mn upfront payment from AbbVie licensing deal

Glenmark shares rose 3% after confirming receipt of $700 million from AbbVie under a global licensing deal for ISB 2001, with milestone payments of up to $1.2 billion

Strides enters into product partnership with Kenox for nasal spray

Strides Pharma Science Ltd on Monday said its Singapore-based subsidiary has entered into a strategic product development partnership with Kenox Pharmaceuticals Inc, which will strengthen the pipeline of nasal spray products across diverse therapeutic areas. Strides Pharma Global Pte, Singapore will collaborate with Kenox on the development and filing of multiple nasal spray products for the US market across diverse therapeutic indications, a joint statement said. The collaboration aims to accelerate affordable, high-quality medicines for patients in the US. However, it also mentioned that specific product details remain confidential at this stage. Kenox is a contract development and manufacturing company specialising in Orally Inhaled and Nasal Drug Products (OINDPs). Strides Pharma Science Executive Director Business Development Aditya Kumar said: "Weannounce this partnership with Kenox, a company that brings deep technical expertise in the OINDP space. Nasal sprays have ...

Glenmark starts multi-nation Phase 3 clinical trials for lung cancer drug

Glenmark Pharmaceuticals on Friday said it has initiated a multi-country Phase 3 clinical trial for Envafolimab, a novel drug for third-stage non-small cell lung cancer. The company said it has received approval from the Drugs Controller General of India to begin patient enrolment and dosing in the country. In parallel, the drug firm has submitted a clinical trial application in Russia and is preparing to open additional clinical trial sites in Brazil and Mexico, Glenmark said in a statement. The randomised, multi-centre, Phase 3 trial will assess the efficacy, safety, pharmacokinetics, and immunogenicity of Envafolimab in patients with third-stage non-small cell lung cancer (NSCLC). Lung cancer remains the leading cause of cancer-related deaths worldwide, with NSCLC comprising around 80-85 per cent of cases. "By advancing this trial across multiple geographies, we are reinforcing our commitment to transforming the standard of care in Stage III NSCLC and addressing one of the grea

Ethical marketing code: Cost of compliance may rise for drug, device firms

UCPMPD 2024 boosts transparency and ethics, but smaller firms may struggle with higher costs and reporting demands

Trump plans hefty tax on imported drugs, risking higher prices, shortages

President Donald Trump has plastered tariffs on products from almost every country on earth. He's targeted specific imports, including autos, steel and aluminium. But he isn't done yet. Trump has promised to impose hefty import taxes on pharmaceuticals, a category of products he's largely spared in his trade war. For decades, in fact, imported medicine has mostly been allowed to enter the United States duty-free. That's starting to change. US and European leaders recently detailed a trade deal that includes a 15 per cent tariff rate on some European goods brought into the United States, including pharmaceuticals. Trump is threatening duties of 200 per cent more on drugs made elsewhere. Shock and awe' is how Maytee Pereira of the tax and consulting firm PwC describes Trump's plans for drugmakers. This is an industry that's going from zero (tariffs) to the potential of 200 per cent.' Trump has promised Americans he'll lower their drug costs. But imposing stiff pharmaceutical tariffs

Aurobindo unit gets UK nod for biosimilar breast cancer drug Dazublys

CuraTeQ Biologics, a subsidiary of Aurobindo Pharma, has secured UK MHRA approval for its trastuzumab biosimilar Dazublys, used in HER2-positive breast and gastric cancer treatment

Akums Drugs announces JV to set up manufacturing facility in Zambia

Akums will hold 51% in its joint venture with the Zambian government to set up a pharma manufacturing facility, marking its first overseas plant and Africa expansion

Eli Lilly to raise UK price of weight-loss drug Mounjaro by 170%

The new price, which also applies to Lilly's type 2 diabetes medicine that has the same name, is effective from September

Mixed Q1 results for top drug firms amid price erosion, tariff threat

Fresh launches boosted growth for players like Lupin, Torrent

Pharma Inc mulls offshore strategy as US tariff fears hit sentiment

Despite current exemptions, Indian pharma firms are preparing for potential US tariffs through offshore units, EU market focus, and sourcing diversification

Indian pharma market grows 7.9% in July, led by chronic therapies

Despite flat volumes, India's pharma market posted 7.9% growth in July on strong demand for chronic therapies like cardiac and diabetes; MAT turnover crossed Rs 2.3 trillion

Eris Lifesciences to target insulin, semaglutide mkt opportunities in FY26

Eris Lifesciences to leverage Novo Nordisk's exit and semaglutide patent expiry, with cartridge capacity and diabetes-focused products planned for commercialisation in FY26